Our Story


Oncoceutics, Inc. is a clinical-stage drug discovery and development company with a novel class compounds that selectively target G protein-coupled receptors for oncology. The first lead compound to result from this program is ONC201, an orally active DRD2 small molecule antagonist that is well-tolerated and effective against advanced cancers. The company has completed a successful Phase I study in solid tumors and is currently conducting additional Phase I/II and Phase II clinical programs in both solid and hematological malignancies. Oncoceutics and collaborative groups have received more than $7 million in grants over the last two years, including grants from the National Cancer Institute, the U.S. Food and Drug Administration, the Pennsylvania Department of Health, and The Musella Foundation. In addition, outside interest in the company’s portfolio has resulted in several R&D alliance agreements between Oncoceutics and leading comprehensive cancer centers, including The University of Texas MD Anderson Cancer Center and the Fox Chase Cancer Center.  The company has established a robust intellectual property position, including several issued patents. Oncoceutics’ pipeline includes ONC201 in multiple trials at various stages, and several analogs with improved and differentiated profiles in preclinical testing.


To safely and durably prolong the lives of cancer patients


To pioneer a novel class of targeted, apoptosis-inducing cancer treatments that avoid toxicity, possess broad anti-tumor activity, and overcome mechanisms of drug resistance by capitalizing on:

  • The unprecedented novelty of our lead asset
  • The wisdom of our esteemed advisors
  • The dedication and collective experience of our management team
  • The support and expertise of our world-class collaborators